Skip to content

Earnings call

Sun Pharmaceutical Industries Q2 FY27 earnings call: Kirti Ganorkar said it usually takes 3, 4 years to build any new product

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Kirti Ganorkar said it usually takes 3, 4 years to build any new product. Emerging Markets business had constant currency growth of 7.6% in the second quarter FY27, driven by product launches across several markets. The IL-23 class remains the dominant and preferred class among clinicians treating psoriasis patients, and Ilumya is unique as an HCP-administered product that supports patients requiring extra care. Emerging Market business contributes almost 20% to its total business.

The numbers management gave

Results

  • Emerging Markets business had constant currency growth of 7.6% in the second quarter FY27, driven by product launches across several markets.
    Show source
    This quarter, we did a constant currency growth of 7.6%.
  • India business grew 17%, in the second quarter FY27.
    Show source
    And in terms of growth, if you have seen AWACS number, the IPM is growing by 1.6% in terms of volume, and we are growing by 6%.
  • India business grew 6% by volume, compared with IPM growth of 1.6% by volume, in the second quarter FY27.
    Show source
    And in terms of growth, if you have seen AWACS number, the IPM is growing by 1.6% in terms of volume, and we are growing by 6%.
  • Volume plus new products accounted for almost 50% to 60% of Sun Pharmaceutical Industries Limited's India business growth, with the rest coming from pricing, in the second quarter FY27.
    Show source
    So almost like 50% to 60% of our growth comes from volume plus new product and the rest is coming from pricing.
  • India business growth is helped by efforts to build brands, conduct scientific promotion, expand its field force, increase prescribers and doctors' prescriptions, launch products ahead of competition and gain market share.
    Show source
    So if I put all of these things together, that is what is helping us to grow both in volume and new product and which is our major growth in last 2 years.

Money and capital

  • Any transaction of the size of the Organon deal will involve one-time costs. Replaced by a later filing.
    Show source
    Dilip Shanghvi: I mean if you want guidance, then you should look at other companies doing large transactions because any transaction of this size will always involve one-time costs.

What it expects ahead

What management expects

  • Kirti Ganorkar said it usually takes 3, 4 years to build any new product.
    Show source
    And usually, our experience is it takes 3, 4 years for you to build any new product.
  • Kirti Ganorkar said GLP-1 drugs will also go through the phase of taking 3, 4 years to build a new product.
    Show source
    So GLP-1 will also go through that phase, yes.
  • The company believes that interventions already in place, coupled with the launch in psoriatic arthritis, will return Ilumya to more typical growth patterns.
    Show source
    And as I mentioned, those interventions, coupled with the launch in psoriatic arthritis, we believe will return Ilumya to more typical growth patterns.
  • The company is increasing coverage of rheumatologists, whose customers are familiar with products like Ilumya; it expects them to begin using the product quickly because these are buy-and-bill products in the United States.
    Show source
    We call them buy-and-bill products in the United States, and we would expect that they would begin to use the product quickly.
  • The company is training its sales force on the updated package insert and will launch over the coming months.
    Show source
    As was mentioned earlier, we've already -- we're training actually our sales force today on the updated package insert, and we'll be launching over the coming months.
  • The company expects its R&D spend to significantly ramp up in the subsequent quarter and expects to meet the overall guidance it has shared as that ramps up.
    Show source
    Dilip Shanghvi: So what I said is that we expect the R&D spend to significantly ramp up in the subsequent quarter.
Show 6 more statements

What management expects

  • The company will leverage markets where it has capabilities and field force to promote products to cardiologists, and will add capabilities in markets where it does not have them in the next couple of months.
    Show source
    And that is what we'll do in the next couple of months.
  • The company cannot give exact detail on how much it will spend on launching PCSK9, but the expense will be part of its overall guidance and the budget it is tracking.
    Show source
    So regarding expenses, we cannot give exact detail on how much we'll spend on launching PCSK9, but it will be part of our overall guidance and the budget, what we are tracking right now.
  • Nidlegy has been filed and Sun Pharmaceutical Industries Limited is awaiting approval.
    Show source
    Dilip Shanghvi: So what I understand is that the product is filed and we are awaiting approval.
  • The company plans to file in all markets as soon as it can, with approval timelines varying by country and some countries requiring local strategies.
    Show source
    Our plan is to file in all the markets as soon as we can.
  • The company will stick to the guidance it gave at the beginning of FY27. Replaced by a later filing.
    Show source
    Regarding the guidance, I think we'll stick to what guidance we have given at the beginning of the year.
  • The company is in a prelaunch phase and will update on its progress from one market to another; it will also announce Nidlegy's commercial launch. Replaced by a later filing.
    Show source
    So right now, what we said, we are in a prelaunch phase, and we'll keep you updated as we move from one market to another market.

What it is building and selling

Demand and pricing

  • The IL-23 class remains the dominant and preferred class among clinicians treating psoriasis patients, and Ilumya is unique as an HCP-administered product that supports patients requiring extra care.
    Show source
    And Ilumya is quite unique in that it's HCP administered and that it really supports patients that require that extra care.
  • The company continues to see plenty of opportunity for Ilumya, which is unique in treating patients who require extra care; many such patients in the United States are on Medicare, where the product does quite well.
    Show source
    And there are a large number of those patients in the United States on Medicare, which is where we do quite well with the product.

Segments

  • Emerging Market business contributes almost 20% to its total business.
    Show source
    So I would say there are a couple of things like you know our Emerging Market business, which contributes almost 20% to total business.
  • The company is present in India and has approval for semaglutide in South Africa and Brazil, where it has commercialized the product, as well as in all the markets it named.
    Show source
    We have approval in South Africa and Brazil and all the markets, we have commercialized the product.
  • Ilumya's loss of exclusivity is not in the foreseeable future.
    Show source
    Abhishek Sharma: It's not in the foreseeable future, Shashank.
  • Understanding is that Nidlegy has a useful place among treatment options available to doctors for these difficult-to-treat patients.
    Show source
    My understanding based on my interaction with the company is that they think that the product has a useful place in the treatment options avail able to doctors for treating this difficult to treat patients.
Show 2 more statements

Segments

  • The company has licensed Nidlegy only for Europe and a few other markets, while Unloxcyt is a global product that the company plans to launch in other markets as it receives approval.
    Show source
    We don't sell it today in other markets, but gradually, as we start getting approval, we will start launching in other markets, whereas Nidlegy, we've licensed only for Europe and a few other markets.

Deals and partners

  • The company is working with a partner on semaglutide in Brazil, and the partner takes all commercial decisions on the product.
    Show source
    So all the commercial decisions on this are taken by partner.

Everything else said on the call

Other

  • Process takes anywhere from 6 months to 12 months, depending on the market and dossier queries.
    Show source
    And usually, this process goes from anywhere from 6 months to 12 months, depending on the market and depending on the dossier kind of queries we can get.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Kunal Dhamesha: First one on the slowdown in growth for Ilumya in US Rick, can you highlight what is driving that? And what kind of actions we have taken? And what's the time line in terms of the recovery in the growth?

    Answer, richard ascroft

    Richard Ascroft: Yes, I don't want to get into the -- all the details, but we have identified a few key things that have led to the slowdown. We put key interventions in place already. And as I mentioned, those interventions, coupled with the launch in psoriatic arthritis, we believe will return Ilumya to more typical growth patterns.

  2. Question

    Kunal Dhamesha: Sure. And just on the psoriatic arthritis front, I cue that maybe the prescription would be generated by a different specialty of doctors. So that kind of investment that needs to be done in terms of sales force or access personnel, is it already there in quarter 2?

    Answer, richard ascroft

    Richard Ascroft: It is. It's already built into our existing sales force model. Some of the prescriptions will be generated by dermatologists, but using the existing sales force, we will increase our reach and also begin calling on rheumatologists.

  3. Question

    Kunal Dhamesha: Sure. And do you foresee any one -off kind of launch expense for the psoriatic arthritis indication?

    Answer, richard ascroft

    Richard Ascroft: We have expenses, but they've been built into our overall budget. They're not extra.

  4. Question

    Kunal Dhamesha: Sure. And second one on the guidance for FY27. I mean, since the first half, we have been clocking at around double -digit top line growth versus our FY27 guidance of high single digit. So at this point in time, is there an update that you want to share? And R&D, I assume that you're going to -- there will be a ramp -up in second half. But just looking at the specialty R&D, it seems like as a percentage of specialty revenue, it has declined to like single digits in this quarter. So is this the ongoing run r ate or there is a phasing out and then there will be some phasing in of clinical trials? How should we think about it? Corporate Office : Sun House, 201 B/1, Western Expre

    Answer, dilip shanghvi

    I'll respond to the R&D. So I think the R&D investment is a function of the start and our ability to recruit subjects in the clinical trial. So we expect that to pick up because we are putting in place appropriate infrastructure in place for that. Kirti will respond to the other question.

    Answer, kirti ganorkar

    Kirti Ganorkar: Yes. Regarding the guidance, I think we'll stick to what guidance we have given at the beginning of the year.

    Answer, richard ascroft

    Richard Ascroft: Maybe let me start with Leqselvi and Unloxcyt, and then I'll move into Ilumya. I think we feel confident about both of the launches. If we start with Unloxcyt, we had some very encouraging news. I think as you heard me share we recently had an update to the NCCN guidelines. And really, what that means now is Unloxcyt is a preferred agent, and that will really help us continue to accelerate access for patients and guide clinician confidence. So that's quite important. The other thing we shared is that we released long-term data with Unloxcyt.

    Answer, richard ascroft

    Not only was the efficacy impressive, but the tolerability, which has been one of the key strengths of Unloxcyt has been durable over time. So we saw a deepening and a durability of response and the tolerability as well. I had a chance to meet with a number of key opinion leaders at ESMO, and they were very impressed with this new data. So we believe both of those 2 things will be a catalyst for Unloxcyt and will continue to accelerate growth. Already, we see month-over-month improvements in share. I would say the same for Leqselvi. We also recently announced new data for Leqselvi.

    Answer, richard ascroft

    Right now that what we hear from physicians is the speed that we've talked about Leqselvi is playing out in their patients. What's nice about the new data is it also shows that in addition to the speed, we see a durability of the efficacy that we saw in our initial published clinical results. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Anand Kadkol, +91 22 43245373, anand.kadkol@sunpharma.com, Sun Pharma Q2 FY27 Earnings Call Transcript 06:30 pm October 30, 2026 As it relates to psoriatic arthritis, it is a new indication for us. The benefits of the product remain the same. So Ilumya in treating psoriatic arthritis will be the only IL-23 that is physician administered, making it the perfect choice for patients that require extra care and benefit from HCP administration. And it's also the only HCP- administered product for psoriatic arthritis that rheumatologists can use to treat patients quarterly. The other HCP administered products are used on a much more frequent basis, making them more inconvenient for patients.

    Answer, richard ascroft

    We are increasing, as I mentioned, to cover rheumatologists and those customers are familiar with products like Ilumya. We call them buy-and-bill products in the United States, and we would expect that they would begin to use the product quickly. As was mentioned earlier, we've already -- we're training actually our sales force today on the updated package insert, and we'll be launching over the coming months.

  5. Question

    Neha Manpuria: That's very helpful. And second, Dilip sir, on the R&D, is it fair to assume you're hitting the 6% to 7% guidance for the full year for R&D spend when we mentioned the second half catch up?

    Answer, dilip shanghvi

    Dilip Shanghvi: So what I said is that we expect the R&D spend to significantly ramp up in the subsequent quarter. And our expectation is that as that ramps up, we should be able to meet the overall guidance that we've shared with people.

    Answer, kirti ganorkar

    Kirti Ganorkar: Your question is quite broad. So I would say there are a couple of things like you know our Emerging Market business, which contributes almost 20% to total business. So there are many markets where we have capabilities and field force to promote product to cardiologists. And that is what we will leverage. There are some markets where we don't have capabilities where we need to go and add those. And that is what we'll do in the next couple of months. So regarding expenses, we cannot give exact detail on how much we'll spend on launching PCSK9, but it will be part of our overall guidance and the budget, what we are tracking right now.

  6. Question

    Damayanti Kerai: Okay. Then my second question is on semaglutide, where you mentioned your partner has launched in Brazil. So can you update us regarding how you are looking to file this product in other markets, like which will be the key markets where you intend to enter in next 1 to 2 years' time frame?

    Answer, kirti ganorkar

    Kirti Ganorkar: I think in last call also, we guided all of you that we don't inform where we have filed and we will get approval for semaglutide. But at the same time, you know we are present in India. We have approval in South Africa and Brazil and all the markets, we have commercialized the product.

    Answer, richard ascroft

    Richard Ascroft: No, it's really a variety of things. I think there's a bit of market, but frankly, part of it is execution as well, and that's the intervention we put in place. I should just add, though, we continue to see plenty of opportunity for Ilumya. It's quite uniq ue in terms of being able to treat patients with -- that require extra care. And there are a large number of those patients in the United States on Medicare, which is where we do quite well with the product.

    Answer, richard ascroft

    Richard Ascroft: Yes. We don't provide product -specific guidance. What I can share is about one -third of patients with plaque psoriasis also have comorbid psoriatic arthritis.

  7. Question

    Just trying to understand if we look beyond Stelara and probably at other biologics, which we might also include in the competition set for Ilumya, those might also see a loss of exclusivity probably sometime over the next 4, 5 years. Now 2 factors. One is our channel dominance in Part B and then the second is the fact that probably the treatment regimen itself has moved towards IL-23. Now do you see these 2 factors sort of helping us defend our Ilumya franchise in the medium term? Or what is it that you think could change in terms of the market dynamics when you sort of take a 4-, 5-year view here?

    Answer, richard ascroft

    Richard Ascroft: There certainly are changes in the marketplace that we've seen and we'll continue to see. I think you mentioned the most important 2 points, though. The IL-23 class remains the dominant class and the preferred class amongst clinicians in treating psoriasis patients. And Ilumya is quite unique in that it's HCP administered and that it really supports patients that require that extra care. And that is very much a unique attribute to Ilumya that no other product has.

  8. Question

    Shashank Krishnakumar: Got it. Just a related question here. So what is the loss of exclusivity for Ilumya itself that we should be factoring in? Should it be 2030? Or would secondary protection sort of extend beyond that?

    Answer, abhishek sharma

    Abhishek Sharma: It's not in the foreseeable future, Shashank.

  9. Question

    Shashank Krishnakumar: Perfect. Got it. And just one last one, if I could squeeze in. So it seems like this quarter, the US generic business probably on a quarter-on-quarter basis has gone up. Was there any short-term opportunity that we benefited from? Or was it business as usual, if you will?

    Answer, richard ascroft

    Richard Ascroft: Yes, you may have missed it, but I did share in my opening that we launched 5 new products this quarter, which led to the growth.

  10. Question

    Tushar Manudhane: I was referring to the mid-single-digit growth in constant currency basis in Emerging Markets and ROW markets. If you could share what's happening there and what would drive growth going forward?

    Answer, abhishek sharma

    Abhishek Sharma: So as far as EM is concerned, I think there has been a pickup on a quarter-on-quarter basis. This quarter, we did a constant currency growth of 7.6%. And this was again driven by product launches across several markets. So I think your question would be more directed towards ROW where the growth is lower.

Show 15 more questions
  1. Question

    Tushar Manudhane: Even in EM, this is the kind of sustainable growth to think about?

    Answer, abhishek sharma

    Abhishek Sharma: No, we don't guide to any particular growth number. But I think if you look at our historical trend in terms of constant currency, which we report every quarter, broadly, this is the range, plus or minus.

  2. Question

    Tushar Manudhane: Got it. And on ROW side?

    Answer, abhishek sharma

    Abhishek Sharma: We are not guiding to any specific guidance. I think you can refer to...

    Answer, dilip shanghvi

    Dilip Shanghvi: It's covered in the overall...

  3. Question

    Tushar Manudhane: Got it. And just secondly, on R&D, while the medicine pipeline, which is given in the press release, this is one program which we will have start of Phase III. The rest of it are in the stage where either regulatory filing is to happen or let's say, the top line data has to come out. So just trying to understand on the monetary side, where the R&D step-up would happen.

    Answer, dilip shanghvi

    Dilip Shanghvi: You're asking for a level of detailing, which generally is not something that we share because we guide for an overall R&D budget. We don't guide for where we are going to on which product, which market.

  4. Question

    Kunal Dhamesha: Just one on the India business. This 17% growth, I mean, the past couple of quarters also, we've seen strong growth. Is it broad-based in terms of therapy areas? And if you could also share some details on volume growth versus the new product introduction versus pricing? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Anand Kadkol, +91 22 43245373, anand.kadkol@sunpharma.com, Sun Pharma Q2 FY27 Earnings Call Transcript 06:30 pm October 30, 2026 Kirti Ganorkar: What you said i

    Answer, kirti ganorkar

    So all the therapy areas we are present, like there are 12 major therapeutic areas where we are present. We are doing well both in terms of performance on prescription as well as value. And in terms of growth, if you have seen AWACS number, the IPM is growing by 1.6% in terms of volume, and we are growing by 6%. So what I'm trying to say, our growth is quite robust in terms of volume and we are growing by volume and new products. So almost like 50% to 60% of our growth comes from volume plus new product and the rest is coming from pricing. So it's quite a healthy growth in my opinion.

  5. Question

    Kunal Dhamesha: Sure. And the other one for Rick. In terms of the drivers of specialty or innovative medicine, we generally highlight the top 3 molecules, which is basically driving the growth, right, in our commentary. Do you think that Unloxcyt and Leqselvi are close to that top 3 set now?

    Answer, richard ascroft

    Richard Ascroft: I don't think we typically provide rankings of our top products. I think we can say that we mentioned the slowdown in Ilumya. The rest of our portfolio is growing and our many products are contributing to that growth, including our new launches.

    Answer, abhishek sharma

    Abhishek Sharma: But at the same time, Kunal, they're still smaller. And yes, in terms of absolute contribution, products like Odomzo and Cequa, Winlevi would have a far bigger contribution.

  6. Question

    Vishal Manchanda: With respect to the Organon deal, can you share what should be our effective cost of borrowing? And what percentage of the acquisition cost would be attributable to goodwill?

    Answer, jayashree satagopan

    Jayashree Satagopan: So we've been working with our bankers and institutions in terms of finalizing the -- and I think the rate of borrowing should be more or less in line with the current borrowing cost of Organon. As far as your question on goodwill is concerned, I think this will go through the accounting standards and the resultant goodwill on the date of acquisition. So I think it's too early for me to comment on it. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Anand Kadkol, +91 22 43245373, anand.kadkol@sunpharma.com, Sun Pharma Q2 FY27 Earnings Call Transcript 06:30 pm October 30, 2026 Vishal Manchanda: And just one more.

  7. Question

    There's a media article citing that the Indian drug regulator has asked Sun Pharma to discontinue production of ophthalmic products from its Assam plant. Can you comment whether this is true and whether this would have any material adverse impact on our numbers?

    Answer, kirti ganorkar

    Kirti Ganorkar: No, Vishal, I can't comment on what media has reported. But what I can say is that there are 11 ophthalmology products, which we have voluntarily recalled. And we voluntarily initiated a temporary cessation of our manufacturing activities, and we have kept the Indian regulator informed about it. I think what is most important for us is the product quality and patient safety. And we have taken a remedial action so that we can put everything in place shortly.

    Answer, jayashree satagopan

    Jayashree Satagopan: See, you could possibly refer to our annual report where we have disclosed most of the particulars regarding the settlement. I think that will give a fair idea.

  8. Question

    Niharika Agarwal: Okay. And in terms of R&D, so we have 5 novel entities in clinical development, right? So how do we evaluate the commercial potential of these? And how do we look at these going forward -- if you could give any color on it?

    Answer, dilip shanghvi

    Dilip Shanghvi: So I think that is the uncertainty related to R&D because there is, let's say, theoretically, one potential of a product. Now how much of market share we can get is linked with what kind of final clinical outcome we will get. So while we do the business development plan and investment plan, we presume a certain targeted therapeutic outcome. Sometimes the outcome is better than what we've planned. Sometimes we don't achieve what we were looking for. So we have a process by which we decide to invest on a product only if we feel that there will be a decent return on investment after adjusting for risk -adjusted probability of approval. And that's the process that we follow.

  9. Question

    Juhi Kumari: Okay. So we will be seeing some other expenses also incurring in exceptional in the coming quarter as well?

    Answer, jayashree satagopan

    Jayashree Satagopan: Yes. And that is normal as we go through the transactions.

    Answer, dilip shanghvi

    Dilip Shanghvi: I mean if you want guidance, then you should look at other companies doing large transactions because any transaction of this size will always involve one-time costs.

    Answer, kirti ganorkar

    Kirti Ganorkar: So the second part of your question, I can answer. See, in any business, there are risks, so we cannot say in next quarter or following in the next 2 quarters, the same growth will continue or not. So it's very difficult to predict. But in terms of our volume growth and new product growth, I can say we cannot pinpoint only one thing why this growth is coming. We are continuously making an effort to build brands, do scientific promotion, continuously expand the field force, improve the number of prescribers and the prescription from the doctors. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Anand Kadkol, +91 22 43245373, anand.kadkol@sunpharma.com, Sun Pharma Q2 FY27 Earnings Call Transcript 06:30 pm October 30, 2026 So finally, it is outcome of all of this effort, including launches of new product ahead of competition and gaining market share. So if I put all of these things together, that is what is helping us to grow both in volume and new product and which is our major growth in last 2 years.

  10. Question

    Vishal Manchanda: I have a question on Nidlegy. I wanted to know the time lines for approval. And second, also wanted to understand whether this is effective enough to -- so there's another drug called nivolumab, which has also shown data in neoadjuvant melanoma, and that is probably showing better outcomes, but that hasn't been filed so far. So I just wanted to understand your views on how this would compete with nivolumab or whether this would also be positioned as an add -on to nivolumab in the same setting, neoadjuvant setting?

    Answer, dilip shanghvi

    Dilip Shanghvi: So what I understand is that the product is filed and we are awaiting approval. I do not have familiarity with the what you call nivolumab data. However, both of these drugs work through very different approach. And I expect -- my understanding is that there are some subsequent studies where Nidlegy has been administered or given to patients after checkpoint inhibitor treatment, and it has produced improved clinical outcome. So I don't know whether it complements or it competes with checkpoint inhibitor. And ultimately, everything will depend on the label that both the products will get. My understanding based on my interaction with the company is that they think that the product has a useful place in the treatment options avail able to doctors for treating this difficult to treat patients.

  11. Question

    Vishal Manchanda: Got it, sir. And can we say like this can also be a large opportunity like Unloxcyt, while Unloxcyt has not shaped up yet, but can this be a large opportunity in your pipeline?

    Answer, dilip shanghvi

    Dilip Shanghvi: It will not be a comparable opportunity because of 2 reasons. One is that Unloxcyt for us is a global product. We don't sell it today in other markets, but gradually, as we start getting approval, we will start launching in other markets, whereas Nidlegy, we've licensed only for Europe and a few other markets.

    Answer, kirti ganorkar

    And usually, this process goes from anywhere from 6 months to 12 months, depending on the market and depending on the dossier kind of queries we can get. So right now, what we said, we are in a prelaunch phase, and we'll keep you updated as we move from one market to another market. And once we have commercial launch, we'll also announce it.

  12. Question

    Surya Patra: Okay. And how long it would generally take, sir, for taking it to key emerging markets? A couple of years’ time?

    Answer, dilip shanghvi

    Dilip Shanghvi: It all depends on when we get approval. Our plan is to file in all the markets as soon as we can. But different countries have different approval time lines. Some of the countries also require local strategies.

  13. Question

    Surya Patra: So about the semaglutide, See, in fact, this year, since it is the first year of commercialization for a key market like India, that would have supported growth and all that. But considering the adherence, the patient adherence about it and all that, so is it fair to believe that the product or the segment will see a growth in the subsequent year, second year?

    Answer, kirti ganorkar

    Kirti Ganorkar: I think this is first year only. And if you see the GLP-1 drugs, how they perform worldwide, they are doing phenomenally well. So in India also, we need to give some time because you will build a new product over a period of time. And usually, our experience is it takes 3, 4 years for you to build any new product. So GLP-1 will also go through that phase, yes.

  14. Question

    Surya Patra: Okay. Okay. Generally, the penetration levels even in the advanced market looks really low. So that is why this question also.

    Answer, dilip shanghvi

    Dilip Shanghvi: No. But I think you should look at -- even if you get a few percentage of the total patients, it's still going to be a very, very large product. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Anand Kadkol, +91 22 43245373, anand.kadkol@sunpharma.com, Sun Pharma Q2 FY27 Earnings Call Transcript 06:30 pm October 30, 2026 Surya Patra: Sure.

  15. Question

    And if I just ask an extended question on this, sir. See, the market like Brazil and South Africa, whether the price erosion scenario in semaglutide is similar like India?

    Answer, kirti ganorkar

    Kirti Ganorkar: See, like in Brazil, we are working with a partner on this product. So all the commercial decisions on this are taken by partner. And generally, we would not like to talk about pricing because it's also a proprietary information, and we cannot disclose about this in our investor call.

    Answer, jayashree satagopan

    Jayashree Satagopan: So first of all, when I spoke about the cost of debt, it is the weighted average cost of debt of Organon. You would see that some of the bonds were at a much lower rate, which was raised earlier. So one should look at it in totality. Secondly, the NCDs that we issued now is not part of transaction financing. This is part of our normal financing to repay some of our current borrowings. And this is a rupee financing and what we are talking of Organon is mostly dollar and euro. So these are not apples-to-apples to compare.

Questions about this call

When was the Sun Pharmaceutical Industries Q2 FY27 earnings call transcript filed?
Sun Pharmaceutical Industries filed the transcript with the exchange on 4 Nov 2026. This page is built from that transcript.
What does this page list?
27 statements from the transcript across 7 topics, 9 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 25 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Sun Pharmaceutical Industries Q2 FY27 concall: Kirti Ganorkar said it usually takes 3, 4 years to build any new product · DalalOS